cas 1865-83-4|| where to buy 7-Methoxy-1,1-dimethyl-3,4-dihydronaphthalen-2(1H)-one

Product Name:7-Methoxy-1,1-dimethyl-3,4-dihydronaphthalen-2(1H)-one

IUPAC Name:7-methoxy-1,1-dimethyl-1,2,3,4-tetrahydronaphthalen-2-one

: CAS：1865-83-4; Molecular Formula：C13H16O2; Purity：95%

: Catalog Number：CM140627; Molecular Weight：204.27

Packing Unit	Available Stock	Price($)
CM140627-250mg	in stock	Ȏǵ
CM140627-1g	in stock	Ǥůŉ

Inquiry: sales@chemenu.com

For R&D use only.

Inquiry Form

Chemical Name

CAS Number

Quantity*

Required Specifications*
(Assay %, Material Grade etc.)

Contact Name*

Contact Email*

Additional Notes

Verification code*

refresh

Product Details

: CAS NO:1865-83-4; Molecular Formula:C13H16O2; Melting Point:-; Smiles Code:O=C1C(C)(C)C2=C(C=CC(OC)=C2)CC1; Density:

: Catalog Number:CM140627; Molecular Weight:204.27; Boiling Point:; MDL No:MFCD20274514; Storage:

Category Infos

: Naphthalenes; Naphthalene is a hydrocarbon produced by the distillation of coal tar and is an aromatic white crystalline substance. Naphthalene is the most abundant component in coal tar. It is used as an insect repellant and insect fumigant. The compound is used in the manufacture of celluloid, dyes, hydrogenated naphthalenes, oil fumes, smokeless powders and synthetic resins.

Column Infos

: Naphthalenes

: Alectinib; Genentech, a member of the Roche Group, has announced that its ALK inhibitor Alecensa® (Alectinib) met its primary endpoint of disease-free survival (DFS) at a scheduled interim analysis of the phase 3 ALINA trial. Alecensa as adjuvant therapy resulted in statistically significant DFS and clinically meaningful improvement.
Worldwide, lung cancer is one of the most common cancers, with NSCLC accounting for 80% to 85% of all lung cancer cases. Despite adjuvant chemotherapy, about half of patients with early-stage lung cancer experience cancer recurrence after surgery. Recent therapeutic innovations, including immunotherapy, have improved the outlook for some patients with early-stage NSCLC; however, there are currently no ALK inhibitors approved for early-stage ALK-positive disease. Alecensa is the first ALK inhibitor proven in a Phase 3 trial to reduce the risk of disease recurrence or death in patients with early-stage ALK-positive NSCLC.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.

Related Products

529-33-9

341-41-3

573-97-7

2472-22-2

771-15-3

22009-38-7

10420-89-0

16712-64-4

3082-62-0

1141-38-4

13214-70-5

3886-70-2

3906-16-9

3400-33-7

7442-52-6

20717-80-0

960009-55-6

23981-47-7

22009-37-6

2631-61-0

1590-08-5

26673-32-5

63449-68-3

18531-94-7

132095-54-6

13672-07-6

39110-32-2

13185-18-7

2752-87-6

1013-04-3

40604-49-7

78119-82-1

613-17-2

90162-14-4

530-93-8

481-42-5

529-34-0

604-53-5

63785-44-4

871731-74-7

41823-28-3

118693-55-3

51793-09-0

7480-36-6

318-98-9

522-48-5

68449-30-9

1201-74-7

317-79-3

26231-23-2

204530-94-9

2437-16-3

81-86-7

23979-41-1

52927-22-7

130-13-2

2976-75-2

61551-49-3

40675-81-8

21331-43-1

13949-67-2

10470-82-3

30366-94-0

7756-78-7

43038-45-5

5341-58-2

39627-84-4

438531-00-1

56503-96-9

351156-65-5

350997-17-0

351156-60-0

350997-18-1

42882-31-5

52373-02-1

832-89-3

22302-58-5

7732-44-7

7248-26-2

438472-54-9

24310-15-4

36304-47-9

143540-88-9

438219-62-6

438219-93-3

10151-46-9

183111-59-3

443864-73-1

93-36-7

23204-36-6

14233-73-9

15100-93-3

773-99-9

41790-30-1

1592-38-7

198287-32-0

133690-96-7

2006278-33-5

90-15-3

15231-91-1

582-17-2

116230-30-9

1125-78-6

131-91-9

607-24-9

2033-42-3

52727-28-3

571-57-3

569-42-6

117-59-9

82957-06-0

57944-44-2

604-44-4

7469-77-4

948-03-8

135-76-2

35689-26-0

144876-33-5

20816-78-8

16149-05-6

23357-46-2

1261732-17-5

1743-01-7

2241-98-7

39110-74-2

14489-75-9

185669-79-8

23357-52-0

2298-07-9

771-14-2

104484-71-1

7499-66-3

479-27-6

2216-68-4

438-32-4

438-26-6

1261808-45-0

131707-40-9

1241377-74-1

4766-33-0

607-23-8

16452-11-2

63240-26-6

1337523-99-5

13916-98-8

13802-40-9

156390-35-1

2017-68-7

324-42-5

31846-36-3

3880-78-2

389104-55-6

41791-59-7

606-57-5

651735-61-4

6134-55-0

61495-10-1

6315-96-4

65440-41-7

67886-69-5

70504-01-7

71590-31-3

72016-73-0

72019-91-1

84460-89-9

86217-42-7

843644-23-5

21032-12-2

269066-75-3

2979-69-3

30236-02-3

3147-58-8

32908-40-0

315-53-7

315-56-0

37436-34-3

457065-49-5

51062-76-1

51981-66-9

575-08-6

56804-95-6

573-04-6

1093739-87-7

76673-34-2

90401-85-7

92297-66-0

93189-18-5

13101-89-8

2472-13-1

1590-25-6

198226-63-0

130200-58-7

13577-40-7

140377-92-0

13686-49-2

13686-51-6

145485-31-0

144464-64-2

15297-33-3

1634-09-9

160693-12-9

16208-20-1

173471-71-1

1680-51-9

20933-24-8

22272-22-6

93-12-9

2954-50-9

341-92-4

77060-74-3

91307-40-3

93742-85-9

535935-61-6

6843-89-6

727-49-1

82238-92-4

85858-95-3

4711-67-5

5247-86-9

53526-25-3

52218-35-6

53732-47-1

50402-56-7

58349-17-0

58596-07-9

62012-54-8

21880-87-5

137848-28-3

137848-29-4

103030-73-5

91271-31-7

90767-01-4

118201-38-0

94134-18-6

1032959-73-1

103860-60-2

1081-32-9

1220039-98-4

89781-52-2

13772-63-9

138113-07-2

309752-65-6

340825-13-0

32721-21-4

4003-89-8

32178-63-5

5419-82-9

65844-56-6

63823-26-7

67247-13-6

87491-79-0

887574-80-3

110931-79-8

86539-78-8

19125-84-9

51529-97-6

110808-69-0

19634-89-0

481-85-6

57536-86-4

737-89-3

92050-16-3

103987-83-3